Biological Skin Substitutes Market Size
Biological Skin Substitutes Market size was valued at USD 287 million in 2022 and is estimated to account for USD 640 million by 2032. Biological skin substitutes, also known as skin grafts, are medical products used to replace or regenerate damaged or lost skin tissue. Chronic wounds, such as venous leg ulcers, diabetic ulcers and pressure ulcers, are becoming more common.

For instance, according to the NIH data, there are around 9.1 to 26.1 million new cases of diabetic foot ulcers worldwide each year. These wounds often require advanced wound care solutions such as biological skin substitutes, to promote healing. Therefore, as the prevalence of chronic wounds continues to rise, the demand for biological skin substitutes will also increase.
When you're dealing with severe burns or injuries from accidents or surgeries, the wounds can be really complicated. That's where biological skin substitutes come in handy. They act like a platform for your body to repair itself and heal those wounds. For example, let's talk about burns. In India alone, there are about 6 to 7 million cases every year. In the United States, the number of people who die from injuries is over 150,000, and millions more get hurt but don't die. So, with all these burns and injuries happening, we need ways to treat wounds better, and biological skin substitutes are a great option.
Biological Skin Substitutes Market Report Attributes
Report Attribute |
Details |
Base Year | 2022 |
---|
Biological Skin Substitutes Market Size in 2022 | USD 287 Million |
---|
Forecast Period | 2023 to 2032 |
---|
Forecast Period 2023 to 2032 CAGR | 8.4 % |
---|
2032 Value Projection | USD 640 Million |
---|
Historical Data for | 2018 to 2022 |
---|
No. of Pages | 127 |
---|
Tables, Charts & Figures | 213 |
Segments covered | Type, Application, End-use, and Region |
---|
Growth Drivers | - Increasing prevalence of chronic wounds
- Rising number of burn & trauma cases
- Growing adoption of wound care facilities
- Technological advancements in regenerative medicine
|
---|
Pitfalls & Challenges | - Adverse side effects associated with biological skin substitutes
- Lack of reimbursement policies
|
---|
COVID-19 Impact
The COVID-19 pandemic had a detrimental impact on the biological skin substitutes market, primarily due to disruptions in supply chains, reduced demand for non-urgent medical procedures, resource reallocation, financial strain on healthcare system, d, and market uncertainty. These factors collectively led to decreased adoption of biological skin substitutes and deferred treatments for chronic wounds and burns. Therefore, the pandemic significantly hindered the growth and operational dynamics of the market for biological skin substitutes.
Biological Skin Substitutes Market Trends
Imagine if doctors could make new skin right from your own body! That's exactly what's happening with this cool new medical field called regenerative medicine. It's like a superpower for healing wounds better than ever before. These new skin substitutes are like super-advanced Band-Aids. They've been made to act exactly like our real skin, helping cuts and burns heal faster and better. One of these amazing products is a treatment called the RECELL System. It works by taking a tiny bit of your own skin and zapping it into these special "spray-on" cells. When they're sprayed onto a wound, they start growing new skin, making it heal and look more like it used to. It's like having your own built-in skin doctor! Patients and doctors are loving these new treatments, and they're making the whole skin substitute market grow like crazy. So, the next time you get a nasty cut, don't be surprised if your doctor pulls out a spray bottle full of your own magic healing cells.
- The healthcare industry has seen a surge in the establishment and utilization of wound care facilities, including wound care centers and clinics. These facilities are equipped with advanced technologies and expertise to manage and treat complex wounds effectively.
- Therefore, as the awareness and availability of specialized wound care facilities continue to grow, the demand for biological skin substitutes as a part of comprehensive wound care will also rise.
Biological Skin Substitutes Market Analysis
The market by type is categorized into human donor tissue-derived products, acellular animal-derived products, tissue-engineered skin products and biosynthetic skin products. The human donor tissue-derived products segment garnered USD 188 million revenue size in the year 2022. The dominance of the segment can be attributed to their exceptional biological compatibility, proven safety record, and established efficacy.
- These products closely mimic natural human skin, ensuring seamless integration and effective tissue regeneration. Furthermore, their reliability and trustworthiness have been demonstrated through extensive clinical studies and real-world applications, reinforcing their position in the market.
- With regulatory approvals and a well-structured supply chain, they are readily available and accessible to healthcare providers and patients. Moreover, higher patient preference for these products further bolsters their market dominance.
Based on application, the biological skin substitutes market is segmented into acute wounds, chronic wounds, and others. The acute wounds segment for over 59% business share in the year 2022. High segment growth is attributed to their higher incidence, immediate treatment requirements, and positive clinical outcomes.
- These wounds, including surgical incisions, traumatic injuries, and emergency cases, demand swift and effective wound care solutions, making biological skin substitutes the preferred choice.
- Additionally, these products excel in promoting rapid healing, reducing scarring, and supporting surgical procedures, especially in emergency and orthopedic contexts.
Therefore, the widespread utilization and adoption of these products in addressing acute wounds contribute significantly towards the growth of the segment.
The biological skin substitutes market by end-use is categorized into hospitals, ambulatory surgical centers, specialty clinics and others. The hospitals segment garnered USD 143 million revenue size in the year 2022.
- Hospital’s clinical expertise, state-of-the-art facilities, and skilled healthcare workforce make them the primary choice for patients with complex wounds, burns, and surgical needs.
- Furthermore, hospitals also see a high volume of patients, creating substantial demand for biological skin substitutes in various wound care applications. Thus, these products are vital in surgical procedures, emergency care, and wound management, further reinforcing hospitals' dominance in this segment.
U.S. biological skin substitutes market accounted for USD 109 million revenue size in 2022 and is predicted to witness substantial market growth over the analysis timeline.
- The U.S. has solidified its dominant position in the market, primarily attributed to the annual increase in burn injuries. The American Burn Association reports around 486,000 yearly burn injuries, with 40,000 of these cases requiring hospitalization.
- Furthermore, U.S. advanced healthcare infrastructure, leadership in innovative medical practices, high surgical volumes, and accessibility to advanced products contribute to its central role in the market.
Biological Skin Substitutes Market Share
The biological skin substitutes industry is consolidated, with major players such as Mylan N.V., Misonix, Inc., and others dominating the market. These companies are focused on continuous product innovation to secure a significant market share. For instance, Misonix is known for its Theraskin product, which is a biosynthetic skin substitute that combines synthetic materials with biological components to promote wound healing.
Some of the eminent market participants operating in the biological skin substitutes industry include
- Organogenesis Inc
- Smith & Nephew plc
- MiMedx Group, Inc.
- Misonix, Inc. (Bioventus)
- Avita Medical
- Stratatech Corporation (Mallinckrodt Pharmaceuticals)
- BioTissue
- Aroa Biosurgery
- ProgenaCare
- Mimedx Group (MiMedx Group, Inc.)
- Tissue Regenix
- Stryker
- Vericel Corporation
- Integra LifeSciences
Biological Skin Substitutes Industry News
- In January 2023, MiMedx Group, Inc. partnered with Gunze Medical, to introduce EPIFIX, a PURION processed placental tissue allograft, to the Japanese market. EPIFIX acts as a protective barrier for wound healing and offers a human biocompatible extracellular matrix with over 300 regulatory proteins. The collaboration aimed to expand the company's geographical reach, grow its customer base, and boost revenue.
- In October 2021, Bioventus Inc., a global leader in innovations for active healing, acquired Misonix, Inc. This strategic move was anticipated to lead to increased innovation, research, and geographical expansion, ultimately offering more effective wound care solutions to patients and healthcare providers.
Biological skin substitutes market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments
Click here to Buy Section of this Report
By Type, 2018-2032 (USD Million)
- Human donor tissue-derived products
- Acellular animal-derived products
- Tissue-engineered skin products
- Biosynthetic skin products
By Application, 2018-2032 (USD Million)
- Acute wounds
- Chronic wounds
- Other applications
By End-use, 2018-2032 (USD Million)
- Hospitals
- Ambulatory surgical centers
- Specialty clinics
- Other end-users
The above information is provided for the following regions and countries
- North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- UAE
- Rest of Middle East & Africa